pyrroles has been researched along with ezetimibe in 129 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 65 (50.39) | 29.6817 |
| 2010's | 62 (48.06) | 24.3611 |
| 2020's | 2 (1.55) | 2.80 |
| Authors | Studies |
|---|---|
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Ballantyne, CM; Houri, J; LeBeaut, AP; Lipka, LJ; Melani, L; Notarbartolo, A; Sager, PT; Sun, S; Suresh, R; Veltri, EP | 1 |
| SoRelle, R | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Tellier, P | 1 |
| Nash, DT | 1 |
| Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J | 1 |
| Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP | 1 |
| Lipka, L; Maccubbin, D; Mata, P; Melani, L; Ponsonnet, D; Sager, P; Stein, E; Stender, S; Suresh, R; Veltri, E | 1 |
| Diz-Lois, F | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R | 1 |
| Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ | 1 |
| McKenney, JM | 1 |
| Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M | 1 |
| van Heyningen, C | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Ballantyne, CM; Brady, WE; Davies, MJ; Feldman, TA; McKenney, J; Mitchel, YB; Palmisano, J; Shah, A | 1 |
| Barsotti, G; Carpi, A; Consani, C; Manca-Rizza, G; Mantuano, E; Marchetti, V; Panichi, V; Paoletti, S; Sbragia, G; Taccola, D | 1 |
| Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF | 1 |
| Arteaga Ll, A; Maiz G, A; Rigotti R, A | 1 |
| Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C | 1 |
| Blagden, MD; Chipperfield, R | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Amado Señaris, JA; García Unzueta, MT; Otero Martínez, M; Piedra León, M | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Alonso, R; Fernández de Bobadilla, J; Lázaro, P; Mata, N; Mata, P; Méndez, I | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Doggrell, SA | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Derdemezis, C; Elisaf, M; Filippatos, T; Mikhailidis, D; Tselepis, A | 1 |
| Dhaliwal, S; Galloway, S; Jian, L; Johnsen, R; Mamo, JC; Pallebage-Gamarallage, MM | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS | 1 |
| Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Bantly, A; Hamamdzic, D; Mohler, ER; Moore, J; Parmacek, M; Putt, M; Rader, DJ; Shi, Y; Wilensky, RL; Yoder, M; Zhang, L | 1 |
| Böger, R; Eggeling, S; Meinertz, T; Munzel, T; Ostad, MA; Schwedhelm, E; Tschentscher, P; Warnholtz, A; Wenzel, P | 1 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Fildes, JE; Khan, U; Najam, O; Shaw, SM; Williams, SG; Yonan, N | 1 |
| Jeon, TI; Osborne, TF; Seo, YK; Zhu, B | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE | 1 |
| Davignon, J; Dubuc, G | 1 |
| Liang, W; Lu, GP; Wu, CF; Yang, H; Yu, Q; Zhang, DD | 1 |
| Altuntas, Y; Arinc, H; Bolayirli, M; Celebi, H; Dirican, A; Kanat, M; Karagoz, Y; Oguz, A; Sahin, S; Serin, E; Tunckale, A; Yildiz, O | 1 |
| Day, A; Kumar, SS; LaHaye, SA; Lahey, KA | 1 |
| Bangit, JR; Batsell, RR; John, S; Molinella, R; Reddy, KJ; Singh, M; Varghese, S; Zaheer, MS | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Ben-Yehuda, O; Bird, S; Constance, C; Hanson, ME; Jones-Burton, C; Lee, R; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Ciralik, H; Gümüşalan, Y; Kilinc, M; Ozbag, D; Toru, H; Yasim, A | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Achkouty, G; Aydanian, H; Azar, M; Azar, RR; Badaoui, G; Harb, S; Kassab, R; Sarkis, A | 1 |
| Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM | 1 |
| Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Bays, H; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Schunn, H | 1 |
| Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Jensen, E; Leiter, LA; Shah, A; Tershakovec, AM | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S | 2 |
| Bouwels, L; de Leeuw, FE; Enajat, M; Pop, G; Pop-Purceleanu, M; Tendolkar, I; van Kuilenburg, J; van Wingen, G; Zwiers, MP | 1 |
| Cerda, A; Curi, R; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Azar, M; Azar, RR; Badaoui, G; Kassab, R; Sarkis, A; Valentin, E | 1 |
| Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Barbosa, CP; Bersani-Amado, CA; Bracht, A; Bracht, L; Caparroz-Assef, SM; Cuman, RK; Ishii-Iwamoto, EL | 1 |
| Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A | 2 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D | 1 |
| Kawaguchi, R | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| Bandgar, TR; Faruqui, AA | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Ali, J; Baboota, S; Goel, A; Gupta, A; Gupta, RS; Sahni, JK; Semwal, VP; Srinivas, KS | 1 |
| Spence, JD | 1 |
| Gupta, YK; Padhy, BM; Yadav, R | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Hashimoto, Y; Matsue, Y; Matsumura, A; Suzuki, M; Yoshida, M | 1 |
| Lappegård, KT; Pop, G; Pop-Purceleanu, M; Sexton, J; Tendolkar, I; van Heerde, W | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| El-Bagary, RI; El-Sherif, ZA; Elkady, EF; Kadry, AM | 1 |
| Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Jannes, CE; Krieger, JE; Morgan, AC; Pereira, AC; Santos, PC; Santos, RD; Turolla, L | 1 |
| Chang, WT; Huang, SK; Liau, I; Yang, YC | 1 |
| Ballantyne, CM; Blom, DJ; Bolognese, M; Burgess, L; Ceska, R; Hala, T; Kim, JB; Koren, MJ; Lillestol, MJ; Monsalvo, ML; Roth, E; Scott, R; Stein, EA; Toth, PD; Tsirtsonis, K; Wasserman, SM | 1 |
| Adewale, A; Behm, MO; Kerbusch, T; Mandema, J; Vargo, R | 1 |
| Hayashi, T; Hirayama, A; Hiro, T; Ishihara, M; Kodama, K; Komatsu, S; Matsuoka, H; Saito, S; Takayama, T; Ueda, Y | 1 |
| Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH | 1 |
| Aguirre, AC; Barbosa, SP; Bianco, HT; do Amaral, JB; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM | 1 |
| Krysiak, R; Okopien, B | 1 |
| Basso, RG; Cerda, A; Fajardo, CM; Hirata, MH; Hirata, RD | 1 |
| Farrell, GC; Haigh, WG; Ioannou, GN; Savard, C; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Einecke, D | 1 |
| Bays, H; Donahue, S; Gaudet, D; Gouni-Berthold, I; Hanotin, C; Robinson, J; Ruiz, JL; Watts, GF; Weiss, R; Zhao, J | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Tang, X; Wang, L | 1 |
| Cho, JM; Choi, JY; Chun, SW; Chung, JW; Hong, SJ; Hong, YJ; Kim, BJ; Kim, CS; Kim, DH; Kim, HS; Kim, KS; Kim, SH; Kim, TN; Lee, CW; Lee, SA; Lee, SH; Lee, SR; Park, HC; Sung, JH; Yoon, SB | 1 |
11 review(s) available for pyrroles and ezetimibe
| Article | Year |
|---|---|
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
[The role of intestinal absorption blockade in hypercholesterolemia treatment].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Obstruction; Pyrroles | 2004 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2010 |
Liptruzet: a combination of ezetimibe and atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL | 2014 |
60 trial(s) available for pyrroles and ezetimibe
| Article | Year |
|---|---|
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Digestive System; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2003 |
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2004 |
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety | 2005 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2005 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2007 |
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2007 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pilot Projects; Pyrroles | 2008 |
Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Heptanoic Acids; Hospitals, Veterans; Humans; Hypercholesterolemia; Male; Pyrroles | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2008 |
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult | 2009 |
[Effects of different statin regimens on lipid profile and serum metalloproteinases in patients with coronary heart disease].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Metalloproteases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Young Adult | 2009 |
A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Drug Administration Schedule; Estradiol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydrocortisone; Luminescent Measurements; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Testosterone; Treatment Outcome | 2009 |
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2010 |
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers, Pharmacological; Chemokine CCL2; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Atrophy; Azetidines; Biomarkers; Cholesterol; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Memory; Memory Disorders; Neuropsychological Tests; Pyrroles; Temporal Lobe | 2012 |
Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides; Young Adult | 2012 |
Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles; Treatment Outcome | 2011 |
Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles | 2012 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; India; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Azetidines; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2014 |
Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pyrroles; Research Design; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cell-Derived Microparticles; Cholesterol, LDL; Drug Interactions; Endothelial Progenitor Cells; Ezetimibe; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Risk | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors | 2014 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome | 2023 |
58 other study(ies) available for pyrroles and ezetimibe
| Article | Year |
|---|---|
[Ezetimib plus statin combination. A strong duo].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin | 2002 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
A statin for a patient with hyperlipidemia and hepatitis C?
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors | 2004 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
Supratherapeutic response to ezetimibe administered with cyclosporine.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cyclosporine; Drug Interactions; Ezetimibe; Heart Transplantation; Heptanoic Acids; Humans; Hyperlipidemias; Immunosuppressive Agents; Male; Middle Aged; Postoperative Complications; Pyrroles | 2005 |
Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens.
Topics: Acetylcholine; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Function Tests; Middle Aged; Pyrroles | 2005 |
[How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors | 2005 |
[Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Time Factors | 2005 |
Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cyclosporine; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Triglycerides | 2006 |
Severe hepatic side effects of ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Diseases; Male; Middle Aged; Pyrroles; Transaminases | 2006 |
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
[Rhabdomyolysis associated to combined ezetimibe-statin treatment].
Topics: Adult; Alcohol Drinking; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rhabdomyolysis; Risk Factors; Time Factors | 2007 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
[Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Models, Economic; Pyrroles | 2008 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-beta abundance.
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Weight; Cholesterol; Cholesterol, Dietary; Enterocytes; Ezetimibe; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intestinal Absorption; Mice; Mice, Inbred C57BL; Pyrroles; Random Allocation; Triglycerides | 2009 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult | 2008 |
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Atorvastatin; Azetidines; Bone Marrow Cells; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Endothelial Cells; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stem Cells; Swine; Vasodilation | 2009 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients invitro.
Topics: Adult; Aged; Atorvastatin; Azetidines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Ezetimibe; Female; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection | 2009 |
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; Case-Control Studies; Ezetimibe; Female; Genetic Variation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; RNA, Messenger; Serine Endopeptidases; Young Adult | 2009 |
Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
Topics: Allylamine; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pulse Therapy, Drug; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2009 |
Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Catalase; Cholesterol, Dietary; Ezetimibe; Glutathione Peroxidase; Heptanoic Acids; Lipid Metabolism; Lipid Peroxidation; Lipids; Malondialdehyde; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2010 |
Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations.
Topics: Atorvastatin; Azetidines; Calibration; Drug Combinations; Drug Compounding; Drug Stability; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Hypolipidemic Agents; Molecular Structure; Pyrroles; Reproducibility of Results; Simvastatin; Solvents; Spectrophotometry, Ultraviolet; Tablets | 2011 |
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation | 2010 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Azetidines; Caco-2 Cells; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymerase Chain Reaction; Pyrroles; RNA, Messenger; Simvastatin; Time Factors | 2011 |
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
Effects of simvastatin, atorvastatin, ezetimibe, and ezetimibe + simvastatin combination on the inflammatory process and on the liver metabolic changes of arthritic rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Leukocyte Count; Leukocytes; Liver; Liver Function Tests; Perfusion; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles | 2011 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Development and validation of stability-indicating assay method by UPLC for a fixed dose combination of atorvastatin and ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Ezetimibe; Heptanoic Acids; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tablets | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy.
Topics: Aged; Amygdala; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Azetidines; Brain; Cognition; Electrocardiography; Executive Function; Ezetimibe; Female; Heptanoic Acids; Hippocampus; Humans; Image Processing, Computer-Assisted; Inflammation; Magnetic Resonance Imaging; Male; Memory; Neuroimaging; Neuropsychological Tests; Psychomotor Performance; Pyrroles; Reaction Time; Vocabulary | 2013 |
LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma.
Topics: Atorvastatin; Azetidines; Chromatography, Liquid; Ezetimibe; Heptanoic Acids; Humans; Pyrroles; Reproducibility of Results; Tandem Mass Spectrometry | 2014 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Brazil; Cholesterol, LDL; Ezetimibe; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Pyrroles; Receptors, LDL | 2014 |
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish | 2014 |
Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses.
Topics: Atorvastatin; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Models, Biological; Pyrroles; Therapeutic Equivalency | 2014 |
Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Azetidines; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2014 |
The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels.
Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperandrogenism; Hypercholesterolemia; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Treatment Outcome; Young Adult | 2015 |
Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Survival; Cells, Cultured; Down-Regulation; Endothelium, Vascular; Ezetimibe; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Luminescence; MicroRNAs; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Real-Time Polymerase Chain Reaction; Simvastatin | 2015 |
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Heptanoic Acids; Inflammasomes; Kupffer Cells; Liver; Mice; Mice, Mutant Strains; Non-alcoholic Fatty Liver Disease; Pyrroles | 2015 |
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.
Topics: Activities of Daily Living; Anticholesteremic Agents; Aspirin; Atorvastatin; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Cholesterol, LDL; Ezetimibe; Humans; Leptin; Pyrroles; Treatment Outcome; Triglycerides | 2022 |